Blog
Heidi Hagen
Heidi Hagen
Heidi Hagen is the Chief Strategy Officer and a Co-founder of Vineti.
April 2, 2020

Advanced therapies in the COVID-19 pandemic: five guidelines for moving forward

The COVID-19 pandemic presents all of us with a dynamic, disruptive challenge unlike anything most of us have experienced in...

March 18, 2020

Quality Management Systems for advanced therapies, Part 5: what does a successful QMS look like in advanced therapies?

Note: this post is the fifth, and final post, in a five-part series on Quality Management Systems (including cGMP and...

March 11, 2020

Quality Management Systems for advanced therapies, Part 4: practical tips for de-risking the critical risks in the advanced therapy supply chain

Note: this post is the fourth in a five-part series on Quality Management Systems (including cGMP and Quality Risk Management)...

March 3, 2020

Quality Management Systems for advanced therapies, Part 3: a risk based approach – what does this mean for advanced therapies?

Note: this post is the third in a five-part series on Quality Management Systems (including cGMP and Quality Risk Management)...

February 25, 2020

Quality Management Systems for advanced therapies, Part 1: the essentials

Note: this post is the first in a five-part series on Quality Management Systems (including cGMP and Quality Risk Management)...

February 25, 2020

Quality Management Systems for advanced therapies, Part 2: six areas of focus

Note: this post is the second in a five-part series on Quality Management Systems (including cGMP and Quality Risk Management)...

February 21, 2020

Data management for advanced therapies, Part 8: the benefits of a strategic approach

Note: this post is the eighth in an eight-part series on data management strategies for personalized therapeutics, such as cell...

February 19, 2020

Data management for advanced therapies, Part 7: summing up the strategies

Note: this post is the seventh in an eight-part series on data management strategies for personalized therapeutics, such as cell...

February 12, 2020

Data management for advanced therapies, Part 6: efficiencies across the supply chain

Note: this post is the sixth in an eight-part series on data management strategies for personalized therapies, such as cell...

February 11, 2020

Data management for advanced therapies, Part 5: traceability

Note: this post is the fifth in an eight-part series on data management strategies for personalized therapies, such as cell...

February 5, 2020

Our Series C and the road ahead

Today, we announced Vineti’s $35 million Series C round of investment. A first-of-its-kind investor coalition of industry leaders — Cardinal Health,...

January 30, 2020

Data management for advanced therapies, Part 4: working with multiple stakeholders

Note: this post is the fourth in an eight-part series on data management strategies for personalized therapies, such as cell...